Mass spectrometry (MS) enables sensitive and accurate quantification of protein biomarkers in biological samples. At CellCarta,bioanalytical mass spectrometry is centered on the MRM platform,which provides targeted,quantitative insights into biomarkers of interest. The MRM platform uses triple quadrupole or hybrid triple quadrupole/linear ion trap mass spectrometers coupled to liquid chromatography,offering superior specificity,sensitivity,and quantification of analytes across clinical samples.
"},{"faq_question":"What sample types can MS analyze?","faq_answer":"One of the main benefits of the MS platform is its flexibility and versatility,accommodating a vast array of sample types and conditions. This makes MS the ideal candidate for processing both common and uncommon biological matrices,including plasma,serum,cells,fresh tissue,frozen tissue,formalin-fixed paraffin-embedded (FFPE) tissue,urine,cerebrospinal fluid (CSF),sputum,vitreous humor,and aqueous humor.
"},{"faq_question":"What regulatory environments do your MS assays operate under?","faq_answer":"CellCarta’s mass spectrometry assays are performed under Good Clinical Laboratory Practice (GCLP) and CAP/CLIA environments. For Immuno-MRM specifically,assay validation follows CPTAC guidelines,an internationally recognized standard for quantitative proteomics. All assay parameters,including specificity,interference,carryover,precision and accuracy,and matrix effects,are comprehensively characterized within CAP-accredited and CLIA-certified laboratory environments.
"},{"faq_question":"What clinical trial phases do your MS assays support?","faq_answer":"CellCarta’s mass spectrometry assays are designed to support all phases of clinical trials. The MRM platform accommodates multiple approaches depending on program stage,including exploratory research,multiplexed relative quantification for rapid biomarker candidate screening in early phases,and fully validated absolute quantification for clinical applications and regulatory submission in later phases. Both custom and off-the-shelf options are available that can match the timeline of each stage.
"}]}#-supreme-cellcarta-service-blocks-8-711{blocks-data:[{"image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-18-2-1-1-scaled.jpg","image_alt":"Biomarker quantification LC-MRM/MS multiplexed workflow across clinical sample types","title":"Biomarker Quantification","description":"Multiplexed biomarker quantification using LC-MS and immunoassays across a vast range of clinically relevant sample types.","button_text":"Discover","button_url":"/capabilities/proteomics/biomarker-quantification/","button_target":"_self"},{"image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-14-2-scaled.jpg","image_alt":"LC-MS/MS unbiased proteomics discovery for novel biomarker identification","title":"Unbiased Discovery","description":"LC-MS/MS for novel biomarker identification.","button_text":"Discover","button_url":"/capabilities/proteomics/unbiased-discovery/","button_target":"_self"},{"image":"https://cellcarta.com/wp-content/uploads/2026/07/Olink_PEA_Enhanced.png","image_alt":"Olink PEA proximity extension assay technology for ultra-sensitive protein biomarker quantification","title":"Olink® PEA Technology","description":"Quantify protein biomarkers using just 1µL of blood with high sensitivity and specificity. ","button_text":"Discover","button_url":"/capabilities/immunoassay-services/olink-pea-technology/","button_target":"_self"}]}#-supreme-cellcarta-tab-content-4-711{oxy-supreme-cellcarta-tab-content-content-heading-tag:h3;oxy-supreme-cellcarta-tab-content-content-heading-size:default;oxy-supreme-cellcarta-tab-content-content-body-size:default;tabs-data:[{"tab_title":"Flexible Analysis","content_title":"","content_body":"Our MS services are powered by liquid chromatography coupled with multiple reaction monitoring (MRM),providing highly specific quantitative insights into your biomarkers of interest. MRM’s targeted approach provides highly specific quantitative insights into your biomarkers of interest.
\nMRM-based analysis can be performed on any species or matrices,including:
\nCellCarta offers a vast selection of off-the-shelf MS assays that can be rapidly implemented for proteomic analysis. Furthermore,custom panels can be developed and tailored to suit your study’s specifications,no matter the complexity.
\nWhether your program requires a research-grade assay for rapid biomarker evaluation or a clinically validated assay for regulatory submission,we can develop panels of any scale for all clinical endpoints.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-52-2-3-scaled.jpg","image_alt":"Scientist reviewing off-the-shelf and custom mass spectrometry panel development options"},{"tab_title":"Leading Platforms","content_title":"","content_body":"All panels are run using our suite of cross-validated triple quadrupole and high-resolution MS platforms for sensitive biomarker and post-translational modification analysis.
\nOur advanced automation platforms support diverse workflows across sample preparation and processing,improving efficiency,reproducibility,and throughput while maintaining analytical quality.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-18-2-1-1-scaled.jpg","image_alt":"Sciex 6500 and Thermo Fisher mass spectrometry platforms in CellCarta laboratory"},{"tab_title":"Multiplex Capabilities","content_title":"","content_body":"When studies require multiplex protein biomarker analysis,our LC-MS platforms can confidently quantify multiple analytes in a single run from a variety of complex biological matrices.
\nRegardless of your study’s scale,our flexible protein quantification panels can range from a few targets to large multiplex assays,supporting absolute,relative,or hybrid quantification.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/07/Trust-building-element-121.jpg","image_alt":"Scientist performing multiplexed mass spectrometry analysis of post-translational modifications in clinical samples"}]}#-supreme-cellcarta-testimonials-16-901{items-data:[{"quote":"\"I turn to CellCarta for my most challenging samples and assay needs. Their mass spec team has a strong reputation for delivering robust,reliable data on tight timelines using advanced technologies for difficult analytical challenges.\"","author_name":"Scientist","author_role":"","author_company":"Biopharma"}]}